pyrroles has been researched along with mdv 3100 in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Corn, PG; Dayyani, F; Gallick, GE; Logothetis, CJ | 1 |
| Cordonnier, T; Crafter, C; Davies, BR; Fazli, L; Gleave, ME; Kim, S; Toren, P; Zoubeidi, A | 1 |
| Dervan, PB; Kurmis, AA; Nickols, NG; Welch, TR; Yang, F | 1 |
| Thoma, C | 1 |
| Austin, D; Chau, B; Foos, K; Hamilton, N; Márquez-Garbán, D; Pietras, R; Sanchez, R; Vadgama, J; Wu, Y | 1 |
| Guo, Z; He, J; Huang, C; Huang, H; Jiang, L; Liao, Y; Liu, J; Liu, Y; Wang, X; Xia, X | 1 |
| Banerji, U; Bianchini, D; Carreira, S; Crespo, M; de Bono, JS; Figueiredo, I; Flohr, P; Hall, E; Kolinsky, MP; Lambros, M; Leonard, L; Luo, J; Mateo, J; Mehra, N; Michalarea, V; Miranda, S; Nava Rodrigues, D; Plymate, S; Porta, N; Raynaud, FI; Rescigno, P; Riisnaes, R; Ruddle, R; Sharp, A; Slade, R; Swales, KE; Tovey, H; Tunariu, N; Welti, J; Zafeiriou, Z | 1 |
| Birtle, AJ; Crabb, SJ; Downs, N; Dunkley, D; Ellis, M; Griffiths, G; Jones, RJ; Khoo, V; Light, M; Northey, J; Radford, M; Whitehead, A; Wilding, S | 1 |
1 review(s) available for pyrroles and mdv 3100
| Article | Year |
|---|---|
Novel therapies for metastatic castrate-resistant prostate cancer.
Topics: Androstenes; Androstenols; Angiogenesis Inhibitors; Anilides; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Atrasentan; Benzamides; Bevacizumab; Biomarkers, Tumor; Bone Remodeling; Cancer Vaccines; Clinical Trials as Topic; Clusterin; Dasatinib; Denosumab; Endothelin-1; Humans; Immunotherapy; Indoles; Ipilimumab; Male; Mice; Mice, SCID; Molecular Targeted Therapy; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms; Pyridines; Pyrimidines; Pyrroles; Pyrrolidines; RANK Ligand; Receptor Cross-Talk; Receptors, Androgen; Signal Transduction; Sunitinib; Taxoids; Thiazoles; Tissue Extracts; Treatment Failure; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2011 |
2 trial(s) available for pyrroles and mdv 3100
| Article | Year |
|---|---|
A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Male; Nitriles; Phenylthiohydantoin; Phosphatidylinositol 3-Kinases; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Treatment Outcome | 2020 |
Overall Survival Update for Patients with Metastatic Castration-resistant Prostate Cancer Treated with Capivasertib and Docetaxel in the Phase 2 ProCAID Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Phosphatidylinositol 3-Kinases; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptors, Androgen; Treatment Outcome | 2022 |
5 other study(ies) available for pyrroles and mdv 3100
| Article | Year |
|---|---|
Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Male; Nitriles; Phenylthiohydantoin; Prostate; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptors, Androgen; Signal Transduction; Treatment Outcome; Xenograft Model Antitumor Assays | 2015 |
A Pyrrole-Imidazole Polyamide Is Active against Enzalutamide-Resistant Prostate Cancer.
Topics: Animals; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Male; Mice; Nitriles; Nylons; Phenylthiohydantoin; Prostatic Neoplasms; Pyrroles; Receptors, Androgen; Receptors, Glucocorticoid; Xenograft Model Antitumor Assays | 2017 |
Prostate cancer: Targeting the core of resistance.
Topics: Benzamides; Humans; Male; Nitriles; Nylons; Phenylthiohydantoin; Prostatic Neoplasms; Pyrroles | 2017 |
Receptors for Insulin-Like Growth Factor-2 and Androgens as Therapeutic Targets in Triple-Negative Breast Cancer.
Topics: Androgen Antagonists; Androgens; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Humans; Insulin-Like Growth Factor II; Molecular Targeted Therapy; Nitriles; Phenylthiohydantoin; Pyrazoles; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Signal Transduction; Triazines; Triple Negative Breast Neoplasms | 2017 |
Inhibition of USP14 enhances the sensitivity of breast cancer to enzalutamide.
Topics: Animals; Benzamides; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 3-Ring; Humans; MCF-7 Cells; Mice; Nitriles; Phenylthiohydantoin; Pyrroles; Pyrrolidines; Signal Transduction; Ubiquitin Thiolesterase; Xenograft Model Antitumor Assays | 2019 |